Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – Stock analysts at Roth Capital issued their Q1 2017 EPS estimates for Catalyst Pharmaceuticals in a research note issued to investors on Monday. Roth Capital analyst S. Henry forecasts that the firm will post earnings of ($0.06) per share for the quarter. Roth Capital also issued estimates for Catalyst Pharmaceuticals’ Q2 2017 earnings at ($0.06) EPS, Q3 2017 earnings at ($0.06) EPS and Q4 2017 earnings at ($0.07) EPS.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, March 15th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02.
var userip;Your IP Address: document.write(userip);
Other research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Monday. Zacks Investment Research cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 5th.
Catalyst Pharmaceuticals (NASDAQ:CPRX) opened at 1.66 on Tuesday. The firm’s market capitalization is $137.56 million. The company’s 50-day moving average price is $1.17 and its 200-day moving average price is $1.14. Catalyst Pharmaceuticals has a 1-year low of $0.51 and a 1-year high of $1.81.
Hedge funds have recently bought and sold shares of the company. Kingdon Capital Management L.L.C. acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at about $794,000. Baker BROS. Advisors LP acquired a new stake in Catalyst Pharmaceuticals during the third quarter valued at about $5,561,000. Berson & Corrado Investment Advisors LLC boosted its stake in Catalyst Pharmaceuticals by 76.1% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 181,900 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 78,600 shares during the last quarter. Finally, Royal Bank of Canada acquired a new stake in Catalyst Pharmaceuticals during the second quarter valued at about $117,000. 28.13% of the stock is currently owned by institutional investors.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.